Skip to content
CryoPort, Inc. logo

CryoPort, Inc.

CYRX

Cryoport is a leading global provider of integrated, temperature-controlled supply chain solutions specifically designed for the life sciences industry, with a primary focus on the cell and gene therapy (CGT) market.

Market cap
$763.6M+102%
Revenue$182.9M+14.0%
Net income$75.7M+166%
Free cash flow-$23.8M+29.8%
EPS (diluted)$1.34+154%
Trailing twelve months · change vs. prior year

Earnings

Next report

Aug 6, 2026 (In 1 week)
Revenue estimate$48.2M
EPS estimate-$0.20

Financials

Q1 2026

Income statement

See full
Revenue$47.8M+16.5%
Gross profit$21.9M+17.6%
Operating income-$9.6M-33.6%
Net income-$10.5M+12.0%
EPS (diluted)-$0.25+10.7%

Balance sheet

See full
Cash & equivalents$272.9M+656%
Total debt$230.7M+293%
Total equity$495.0M+24.1%
Total assets$763.6M+9.1%

Cash flow

See full
Operating cash flow$3.7M+186%
CapEx$10.0M+215%
Free cash flow-$6.2M+16.8%

Valuation & ratios

Valuation

See full
Market cap$763.6M+102%
Enterprise value$721.43M+291%
P/E10.1×
P/S4.2×+1.9×

Profitability

See full
Gross margin47.2%+1.6pp
Operating margin-21.4%-8.8pp
FCF margin-13%-3.6pp

Returns & leverage

See full
Debt / equity0.5×+0.3×
Current ratio2.1×-3.5×

Segments

By geography

See full
Americas$35.0M+8.6%
EMEA$9.0M+60.4%
Asia Pacific$3.9M+19.1%

By segment

See full
Life Sciences Services$27.9M
Life Sciences Products$20.9M

By product

See full
Biologistics Solutions$21.7M+16.9%
Biostorage Bioservices$5.2M+20.7%

Competitors

Profile

Cryoport is a leading global provider of integrated, temperature-controlled supply chain solutions specifically designed for the life sciences industry, with a primary focus on the cell and gene therapy (CGT) market. The company offers end-to-end logistics, cryogenic storage, and specialized equipment to ensure the integrity of high-value, temperature-sensitive biological materials from preclinical research through commercial distribution. Its value proposition centers on a 'Chain of Compliance' that integrates advanced informatics with physical infrastructure to support complex therapies.

Competitive position

Cryoport is a market leader in the specialized CGT supply chain niche, distinguished by its end-to-end digital integration and proprietary 'Chain of Compliance' framework.

GeographiesAmericas, EMEA, APAC
Customer segmentsBiopharmaceutical, Cell and Gene Therapy (CGT), Animal Health, Reproductive Medicine, Government and Research
Business modelManufacturing, Service-based logistics, SaaS (Informatics), Biostorage and fulfillment
SuppliersRaw material suppliers, Component manufacturers, Specialized sensor and IoT technology providers, Leukapheresis collection centers
CustomersPharmaceutical manufacturers, Clinical trial sponsors, Hospitals and points of care, Agricultural and animal breeding facilities
Listed1993
Employees1.2K
CEOJerrell W. Shelton
FilingsSEC EDGAR

Questions, answered.

What is CryoPort, Inc.'s market cap?
CryoPort, Inc. (CYRX) has a market capitalization of $763.6M and trades on NASDAQ.
What is CryoPort, Inc.'s revenue and profitability?
CryoPort, Inc. generated $182.9M in trailing twelve-month revenue with net income of $75.7M, representing a net margin of 39.2%. Gross margin stands at 47.2%, with free cash flow of -$23.8M. These figures are based on the Q1 2026 filing.
Who are CryoPort, Inc.'s competitors?
CryoPort, Inc.'s key competitors include Azenta Life Sciences, UPS Healthcare, World Courier, and others. These companies compete in similar markets and product categories.
Who does CryoPort, Inc. partner with?
CryoPort, Inc.'s notable partners include DHL Supply Chain, Moffitt Cancer Center.
What subsidiaries does CryoPort, Inc. have?
CryoPort, Inc.'s subsidiaries include MVE Biological Solutions, CryoGene, Tec4med.
Where is CryoPort, Inc. headquartered?
CryoPort, Inc. is headquartered in United States of America and employs approximately 1,170 people. It has been publicly traded since 1993.